Guanghua School of Stomatolagy, Hospital of Stomatology Sun Yat-sen University
Guangzhou, Guangdong, 510055, China
Location status: Recruiting
Location contact
Cheng Wang, PhD
CONTACT
Jinsong Hou, PhD
CONTACT
NCT Number: NCT02743832
The purpose of this study is to determine whether cervical lymph node dissection is necessarily performed in the presence of early-stage oral squamous cell carcinoma.
Interested in participating?
Request Info20 year–70 year
All sexes
Interventional
Not applicable
Guangzhou, Guangdong, 510055, China
Location status: Recruiting
Cheng Wang, PhD
CONTACT
Jinsong Hou, PhD
CONTACT
Oral squamous cell carcinoma is the most common malignant tumor of oral and maxillofacial region, and prone to early cervical lymph node metastases. Lymphatic spread is associated with increased risk of loco-regional recurrence, therefore, the identification of lymph node metastases preoperatively is very important for the optimal surgical therapy. Recently, cervical lymph node dissection(CLND) is performed in the presence of oral squamous cell carcinoma. However, whether cervical lymph node dissection is necessarily performed in the presence of early-stage oral squamous cell carcinoma is still controversial. CLND will represent over-treatment in some case of early-stage oral squamous cell carcinoma. Therefore, How to accurately predict whether a patient should be performed CLND is important. Our previous study show that tumor budding is closely related to lymphatic spread in the oral squamous cell carcinoma. The purpose of this study is to find that whether the tumor budding guide the individualized surgical planning of early-stage oral squamous cell carcinoma.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Resection for primary lesion and cervical lymph node dissection are performed in the early-stage oral squamous cell carcinoma.
Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma.
Time frame: After the first year, review every three months at a time;The next four years, review every six months at a time.
The time from the first operation to death was recorded
Time frame: After the first year, review every three months at a time;The next four years, review every six months at a time.
The time from the start of surgery to the discovery of the first cervical lymphatic metastases
Time frame: After the first year, review every three months at a time;The next four years, review every six months at a time.
To investigate the local recurrence rate and the recurrence rate of cervical lymphatic metastasis.
Time frame: After the first year, review every three months at a time;The next four years, review every six months at a time.
Complete the University of Washington Quality of Life Form (UW-QOL) To understand the quality of life of patients after surgery.
Contact information is provided by the study sponsor or research team.
Cheng Wang, PhD
CONTACT
Jinsong Hou, PhD
CONTACT
Jinsong Hou
Other
A Randomized,Multicenter,Prospectie,Controlled Clinical Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07339176
Breast Diseases, Breast Neoplasms
Los Angeles, California, United States
View Trial DetailsNCT04892173
Carcinoma, Carcinoma, Squamous Cell
Birmingham, Alabama, United States
View Trial DetailsNCT04564989
Carcinoma, Carcinoma, Squamous Cell
Rochester, Minnesota, United States
View Trial DetailsNCT04429542
Adnexal Diseases, Carcinoma
La Jolla, California, United States
View Trial Details